메뉴 건너뛰기




Volumn 7, Issue 1, 2012, Pages

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

EID: 84855833408     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030275     Document Type: Review
Times cited : (220)

References (88)
  • 2
    • 79952360701 scopus 로고    scopus 로고
    • Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden
    • doi:10.1136/ard.2010.133371
    • Neovius M, Simard JF, Askling J, (2011) Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Annals of the rheumatic diseases 70: 624-629 doi:10.1136/ard.2010.133371.
    • (2011) Annals of the Rheumatic Diseases , vol.70 , pp. 624-629
    • Neovius, M.1    Simard, J.F.2    Askling, J.3
  • 3
    • 0036316513 scopus 로고    scopus 로고
    • The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
    • doi:10.1093/rheumatology/41.7.793
    • Symmons D, Turner G, Webb R, Asten P, Barrett E, et al. (2002) The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 41: 793-800 doi:10.1093/rheumatology/41.7.793.
    • (2002) Rheumatology , vol.41 , pp. 793-800
    • Symmons, D.1    Turner, G.2    Webb, R.3    Asten, P.4    Barrett, E.5
  • 4
    • 0034121235 scopus 로고    scopus 로고
    • Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins
    • Gregor AJMAC, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, et al. (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis & Rheumatism 43: 30-37.
    • (2000) Arthritis & Rheumatism , vol.43 , pp. 30-37
    • Gregor, A.J.M.A.C.1    Snieder, H.2    Rigby, A.S.3    Koskenvuo, M.4    Kaprio, J.5
  • 5
    • 38549176118 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonist mechanisms of action: a comprehensive review
    • doi:10.1016/j.pharmthera.2007.10.001
    • Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP, (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacology & therapeutics 117: 244-279 doi:10.1016/j.pharmthera.2007.10.001.
    • (2008) Pharmacology & Therapeutics , vol.117 , pp. 244-279
    • Tracey, D.1    Klareskog, L.2    Sasso, E.H.3    Salfeld, J.G.4    Tak, P.P.5
  • 6
    • 70349140060 scopus 로고    scopus 로고
    • Biologics for rheumatoid arthritis: an overview of Cochrane reviews
    • Cochrane database of systematic reviews (Online): CD007848. Available:. Accessed 2 May 2011
    • Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, et al. (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane database of systematic reviews (Online): CD007848. Available: http://www.ncbi.nlm.nih.gov/pubmed/19821440. Accessed 2 May 2011.
    • (2009)
    • Singh, J.A.1    Christensen, R.2    Wells, G.A.3    Suarez-Almazor, M.E.4    Buchbinder, R.5
  • 7
    • 70450277098 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis
    • doi:10.1007/s10067-009-1233-9
    • Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF, et al. (2009) A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clinical rheumatology 28: 1365-1373 doi:10.1007/s10067-009-1233-9.
    • (2009) Clinical Rheumatology , vol.28 , pp. 1365-1373
    • Wiens, A.1    Correr, C.J.2    Venson, R.3    Grochocki, M.C.4    Otuki, M.F.5
  • 8
    • 70049118471 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis
    • doi:10.1111/j.1365-3083.2009.02296.x
    • Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, et al. (2009) A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scandinavian journal of immunology 70: 337-344 doi:10.1111/j.1365-3083.2009.02296.x.
    • (2009) Scandinavian Journal of Immunology , vol.70 , pp. 337-344
    • Wiens, A.1    Correr, C.J.2    Pontarolo, R.3    Venson, R.4    Quinalha, J.V.5
  • 10
    • 43549105864 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
    • BMC musculoskeletal disorders 9. Available:. Accessed 14 September 2011
    • Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, et al. (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC musculoskeletal disorders 9. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2377247&tool=pmcentrez&rendertype=abstract. Accessed 14 September 2011.
    • (2008)
    • Alonso-Ruiz, A.1    Pijoan, J.I.2    Ansuategui, E.3    Urkaregi, A.4    Calabozo, M.5
  • 11
    • 67549117204 scopus 로고    scopus 로고
    • The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
    • doi:10.1136/ard.2008.091025
    • Leombruno JP, Einarson TR, Keystone EC, (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Annals of the rheumatic diseases 68: 1136-1145 doi:10.1136/ard.2008.091025.
    • (2009) Annals of the Rheumatic Diseases , vol.68 , pp. 1136-1145
    • Leombruno, J.P.1    Einarson, T.R.2    Keystone, E.C.3
  • 12
    • 77950411921 scopus 로고    scopus 로고
    • Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis
    • doi:10.1592/phco.30.4.339
    • Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R, (2010) Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30: 339-353 doi:10.1592/phco.30.4.339.
    • (2010) Pharmacotherapy , vol.30 , pp. 339-353
    • Wiens, A.1    Venson, R.2    Correr, C.J.3    Otuki, M.F.4    Pontarolo, R.5
  • 13
    • 37349006854 scopus 로고    scopus 로고
    • The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
    • doi:10.1080/03009740701607067
    • Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, et al. (2007) The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scandinavian journal of rheumatology 36: 411-417 doi:10.1080/03009740701607067.
    • (2007) Scandinavian Journal of Rheumatology , vol.36 , pp. 411-417
    • Kristensen, L.E.1    Christensen, R.2    Bliddal, H.3    Geborek, P.4    Danneskiold-Samsøe, B.5
  • 14
    • 79955556837 scopus 로고    scopus 로고
    • Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis
    • doi:10.3899/jrheum.100665
    • Launois R, Avouac B, Berenbaum F, Blin O, Bru I, et al. (2011) Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. The Journal of rheumatology 38: 835-845 doi:10.3899/jrheum.100665.
    • (2011) The Journal of Rheumatology , vol.38 , pp. 835-845
    • Launois, R.1    Avouac, B.2    Berenbaum, F.3    Blin, O.4    Bru, I.5
  • 15
    • 0027238592 scopus 로고
    • The American Colloge of Rheumatolgy preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
    • Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, et al. (1993) The American Colloge of Rheumatolgy preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and rheumatism 36: 729-740.
    • (1993) Arthritis and Rheumatism , vol.36 , pp. 729-740
    • Felson, D.T.1    Anderson, J.J.2    Boers, M.3    Bombardier, C.4    Chernoff, M.5
  • 16
    • 0023945481 scopus 로고
    • The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
    • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and rheumatism 31: 315-324.
    • (1988) Arthritis and Rheumatism , vol.31 , pp. 315-324
    • Arnett, F.C.1    Edworthy, S.M.2    Bloch, D.A.3    McShane, D.J.4    Fries, J.F.5
  • 18
  • 19
    • 0028143211 scopus 로고
    • Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
    • Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, et al. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
    • (1994) Lancet , vol.344 , pp. 1105-1110
    • Elliott, M.J.1    Maini, R.N.2    Feldmann, M.3    Kalden, J.R.4    Antoni, C.5
  • 20
    • 0001317444 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis
    • European Etanercept Investigators
    • Ericson ML, Wajdula J, European Etanercept Investigators (1999) A double-blind, placebo-controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis. Arthritis and Rheumatism 42 (Suppl 5): 82.
    • (1999) Arthritis and Rheumatism , vol.42 , Issue.SUPPL. 5 , pp. 82
    • Ericson, M.L.1    Wajdula, J.2
  • 21
    • 75149167060 scopus 로고    scopus 로고
    • Golimumab, a new human Anti-TNF-alpha monoclonal antibody, administered subcutaneously everv 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled, GO-BEFORE study
    • Fleischmann RM, Emery P, Moreland LW, Hsia EC, Strusberg I, et al. (2008) Golimumab, a new human Anti-TNF-alpha monoclonal antibody, administered subcutaneously everv 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled, GO-BEFORE study. Arthritis and Rheumatism 58: 530.
    • (2008) Arthritis and Rheumatism , vol.58 , pp. 530
    • Fleischmann, R.M.1    Emery, P.2    Moreland, L.W.3    Hsia, E.C.4    Strusberg, I.5
  • 23
    • 84982256026 scopus 로고    scopus 로고
    • Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study
    • Huang F, Zhang FC, Bao CD, Tao Y, Gu JR, et al. (2009) [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.]. Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine 48: 916-921.
    • (2009) Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine , vol.48 , pp. 916-921
    • Huang, F.1    Zhang, F.C.2    Bao, C.D.3    Tao, Y.4    Gu, J.R.5
  • 24
    • 0000002244 scopus 로고    scopus 로고
    • Anti-TNF-alpha monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): Results of a double-blind, placebo controlled multicenter trial
    • Kavanaugh AF, Cush JJ, St Clair EW, McCune WJ, Braakman TAJ, et al. (1996) Anti-TNF-alpha monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): Results of a double-blind, placebo controlled multicenter trial. Arthritis and Rheumatism 39: 575.
    • (1996) Arthritis and Rheumatism , vol.39 , pp. 575
    • Kavanaugh, A.F.1    Cush, J.J.2    Clair St., E.W.3    McCune, W.J.4    Braakman, T.A.J.5
  • 25
    • 0034039605 scopus 로고    scopus 로고
    • Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
    • Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P, (2000) Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. The Journal of rheumatology 27: 841-850.
    • (2000) The Journal of Rheumatology , vol.27 , pp. 841-850
    • Kavanaugh, A.1    Clair St., E.W.2    McCune, W.J.3    Braakman, T.4    Lipsky, P.5
  • 26
    • 37149054571 scopus 로고    scopus 로고
    • Improvement in DAS28 response through one-year of golimumab treatment in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo controlled, dose ranging trial
    • Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, et al. (2007) Improvement in DAS28 response through one-year of golimumab treatment in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo controlled, dose ranging trial. Annals of the Rheumatic Diseases 66: 175-176.
    • (2007) Annals of the Rheumatic Diseases , vol.66 , pp. 175-176
    • Kay, J.1    Matteson, E.L.2    Dasgupta, B.3    Nash, P.4    Durez, P.5
  • 27
    • 33845360135 scopus 로고    scopus 로고
    • Das28 responses in patients with active rheumatoid arthritis who received golimumab and methotrexate: A randomized, double-blind, placebo-controlled phase 2 trial
    • Kay J, Matteson EL, Dasgupta B, Nash P, Durezs P, et al. (2006) Das28 responses in patients with active rheumatoid arthritis who received golimumab and methotrexate: A randomized, double-blind, placebo-controlled phase 2 trial. Annals of the Rheumatic Diseases 65: 323.
    • (2006) Annals of the Rheumatic Diseases , vol.65 , pp. 323
    • Kay, J.1    Matteson, E.L.2    Dasgupta, B.3    Nash, P.4    Durezs, P.5
  • 28
    • 0000615070 scopus 로고    scopus 로고
    • The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX)
    • Keystone E, Weinblatt M, Furst D, Weisman M, Moreland L, et al. (2001) The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX). Arthritis and Rheumatism 44: 965.
    • (2001) Arthritis and Rheumatism , vol.44 , pp. 965
    • Keystone, E.1    Weinblatt, M.2    Furst, D.3    Weisman, M.4    Moreland, L.5
  • 29
    • 84871309049 scopus 로고    scopus 로고
    • [Efficacy and safety of infliximab in patients with rheumatoid arthritis]
    • Zhang W, Shi Q, Wu D-H, Bao C-D, Yang N-P, et al. (2009) [Efficacy and safety of infliximab in patients with rheumatoid arthritis]. Zhonghua yi xue za zhi 89: 1876-1880.
    • (2009) Zhonghua Yi Xue Za Zhi , vol.89 , pp. 1876-1880
    • Zhang, W.1    Shi, Q.2    Wu, D.-H.3    Bao, C.-D.4    Yang, N.-P.5
  • 31
    • 0032695387 scopus 로고    scopus 로고
    • Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
    • Antoni C, Kalden JR, (1999) Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clinical & Experimental Rheumatology 17: 73-77.
    • (1999) Clinical & Experimental Rheumatology , vol.17 , pp. 73-77
    • Antoni, C.1    Kalden, J.R.2
  • 32
    • 37248999029 scopus 로고    scopus 로고
    • Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone
    • Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, et al. (2007) Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis & Rheumatism 56: 3919-3927.
    • (2007) Arthritis & Rheumatism , vol.56 , pp. 3919-3927
    • Durez, P.1    Malghem, J.2    Nzeusseu Toukap, A.3    Depresseux, G.4    Lauwerys, B.R.5
  • 33
    • 4344578260 scopus 로고    scopus 로고
    • A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment
    • Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, et al. (2004) A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Annals of the Rheumatic Diseases 63: 1069-1074.
    • (2004) Annals of the Rheumatic Diseases , vol.63 , pp. 1069-1074
    • Durez, P.1    Nzeusseu Toukap, A.2    Lauwerys, B.R.3    Manicourt, D.H.4    Verschueren, P.5
  • 34
    • 0348109372 scopus 로고    scopus 로고
    • Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)
    • Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, et al. (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Journal of Rheumatology 30: 2563-2571.
    • (2003) Journal of Rheumatology , vol.30 , pp. 2563-2571
    • Furst, D.E.1    Schiff, M.H.2    Fleischmann, R.M.3    Strand, V.4    Birbara, C.A.5
  • 35
    • 42949168291 scopus 로고    scopus 로고
    • Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
    • Goekoop-Ruiterman Y, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens P, et al. (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis and rheumatism 58 2 (Suppl): 126-135.
    • (2008) Arthritis and Rheumatism , vol.58 , Issue.2 SUPPL. , pp. 126-135
    • Goekoop-Ruiterman, Y.1    de Vries-Bouwstra, J.K.2    Allaart, C.F.3    van Zeben, D.4    Kerstens, P.5
  • 36
    • 27744514865 scopus 로고    scopus 로고
    • Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial
    • doi:10.1002/art.21405
    • Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis and rheumatism 52: 3381-3390 doi:10.1002/art.21405.
    • (2005) Arthritis and Rheumatism , vol.52 , pp. 3381-3390
    • Goekoop-Ruiterman, Y.P.M.1    de Vries-Bouwstra, J.K.2    Allaart, C.F.3    van Zeben, D.4    Kerstens, P.J.S.M.5
  • 37
    • 0031660364 scopus 로고    scopus 로고
    • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
    • Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism 41: 1552-1563.
    • (1998) Arthritis & Rheumatism , vol.41 , pp. 1552-1563
    • Maini, R.N.1    Breedveld, F.C.2    Kalden, J.R.3    Smolen, J.S.4    Davis, D.5
  • 38
  • 41
    • 33750356014 scopus 로고    scopus 로고
    • Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
    • doi:10.1136/ard.2005.043299
    • van Riel PLCM, Taggart AJ, Sany J, Gaubitz M, Nab HW, et al. (2006) Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Annals of the rheumatic diseases 65: 1478-1483 doi:10.1136/ard.2005.043299.
    • (2006) Annals of the Rheumatic Diseases , vol.65 , pp. 1478-1483
    • van Riel, P.L.C.M.1    Taggart, A.J.2    Sany, J.3    Gaubitz, M.4    Nab, H.W.5
  • 42
    • 34447304070 scopus 로고    scopus 로고
    • A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases
    • Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, et al. (2007) A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 46: 1122-1125.
    • (2007) Rheumatology , vol.46 , pp. 1122-1125
    • Weisman, M.H.1    Paulus, H.E.2    Burch, F.X.3    Kivitz, A.J.4    Fierer, J.5
  • 43
    • 33646379583 scopus 로고    scopus 로고
    • The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial
    • doi:10.1002/art.21734
    • Westhovens R, Yocum D, Han J, Berman A, Strusberg I, et al. (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis and rheumatism 54: 1075-1086 doi:10.1002/art.21734.
    • (2006) Arthritis and Rheumatism , vol.54 , pp. 1075-1086
    • Westhovens, R.1    Yocum, D.2    Han, J.3    Berman, A.4    Strusberg, I.5
  • 44
    • 33745964133 scopus 로고    scopus 로고
    • Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A preliminary study from China
    • Zhang F-C, Hou Y, Huang F, Wu D-H, Bao C-D, et al. (2006) Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A preliminary study from China. APLAR Journal of Rheumatology 9: 127-130.
    • (2006) APLAR Journal of Rheumatology , vol.9 , pp. 127-130
    • Zhang, F.-C.1    Hou, Y.2    Huang, F.3    Wu, D.-H.4    Bao, C.-D.5
  • 45
    • 67650379733 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III,trial
    • Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, et al. (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III,trial. Lancet 374: 210-221.
    • (2009) Lancet , vol.374 , pp. 210-221
    • Smolen, J.S.1    Kay, J.2    Doyle, M.K.3    Landewe, R.4    Matteson, E.L.5
  • 46
    • 34548183243 scopus 로고    scopus 로고
    • Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
    • doi:10.1136/ard.2006.065995
    • Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, et al. (2007) Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Annals of the rheumatic diseases 66: 1233-1238 doi:10.1136/ard.2006.065995.
    • (2007) Annals of the Rheumatic Diseases , vol.66 , pp. 1233-1238
    • Rahman, M.U.1    Strusberg, I.2    Geusens, P.3    Berman, A.4    Yocum, D.5
  • 47
    • 26844551124 scopus 로고    scopus 로고
    • The safety and efficacy of infliximab in RA: 1-year results of a large, randomized, placebo-controlled trial in patients with various comorbidities and background treatments as encountered in clinical practice
    • Yocum D, Wolfe F, Rahman MU, Han J, Berman A, et al. (2004) The safety and efficacy of infliximab in RA: 1-year results of a large, randomized, placebo-controlled trial in patients with various comorbidities and background treatments as encountered in clinical practice. Arthritis and Rheumatism 50: 659-659.
    • (2004) Arthritis and Rheumatism , vol.50 , pp. 659
    • Yocum, D.1    Wolfe, F.2    Rahman, M.U.3    Han, J.4    Berman, A.5
  • 48
    • 84855835045 scopus 로고    scopus 로고
    • Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
    • Keystone, (2009) Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Arthritis and Rheumatism 60: 1249.
    • (2009) Arthritis and Rheumatism , vol.60 , pp. 1249
    • Keystone1
  • 49
    • 30144442293 scopus 로고    scopus 로고
    • A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis
    • Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, et al. (2006) A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. Journal of Rheumatology 33: 37-44.
    • (2006) Journal of Rheumatology , vol.33 , pp. 37-44
    • Abe, T.1    Takeuchi, T.2    Miyasaka, N.3    Hashimoto, H.4    Kondo, H.5
  • 50
    • 84855845925 scopus 로고    scopus 로고
    • The efficacy and safety of abatacept or infliximab in ra patients with an inadequate response to mtx: results from a 1-year double-blind, randomized, placebo-controlled trial
    • Bessette L, Schiff MH, Kieserman M, (2007) The efficacy and safety of abatacept or infliximab in ra patients with an inadequate response to mtx: results from a 1-year double-blind, randomized, placebo-controlled trial. The Journal of rheumatology 34: 1627.
    • (2007) The Journal of Rheumatology , vol.34 , pp. 1627
    • Bessette, L.1    Schiff, M.H.2    Kieserman, M.3
  • 52
    • 11144354315 scopus 로고    scopus 로고
    • Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
    • doi:10.1002/art.20159
    • Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, et al. (2004) Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and rheumatism 50: 1051-1065 doi:10.1002/art.20159.
    • (2004) Arthritis and Rheumatism , vol.50 , pp. 1051-1065
    • Maini, R.N.1    Breedveld, F.C.2    Kalden, J.R.3    Smolen, J.S.4    Furst, D.5
  • 53
    • 0033524159 scopus 로고    scopus 로고
    • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group
    • Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
    • (1999) Lancet , vol.354 , pp. 1932-1939
    • Maini, R.1    Clair St., E.W.2    Breedveld, F.3    Furst, D.4    Kalden, J.5
  • 54
    • 19944431840 scopus 로고    scopus 로고
    • Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-m
    • doi:10.1002/art.20712
    • Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, et al. (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-m. Arthritis and rheumatism 52: 27-35 doi:10.1002/art.20712.
    • (2005) Arthritis and Rheumatism , vol.52 , pp. 27-35
    • Quinn, M.A.1    Conaghan, P.G.2    O'Connor, P.J.3    Karim, Z.4    Greenstein, A.5
  • 55
    • 47949106400 scopus 로고    scopus 로고
    • Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
    • doi:10.1136/ard.2007.080002
    • Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, et al. (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Annals of the rheumatic diseases 67: 1096-1103 doi:10.1136/ard.2007.080002.
    • (2008) Annals of the Rheumatic Diseases , vol.67 , pp. 1096-1103
    • Schiff, M.1    Keiserman, M.2    Codding, C.3    Songcharoen, S.4    Berman, A.5
  • 56
    • 17244364098 scopus 로고    scopus 로고
    • Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomi
    • doi:10.1002/art.20982
    • Smolen JS, Han C, Bala M, Maini RN, Kalden JR, et al. (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomi. Arthritis and rheumatism 52: 1020-1030 doi:10.1002/art.20982.
    • (2005) Arthritis and Rheumatism , vol.52 , pp. 1020-1030
    • Smolen, J.S.1    Han, C.2    Bala, M.3    Maini, R.N.4    Kalden, J.R.5
  • 57
    • 33644895018 scopus 로고    scopus 로고
    • Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial
    • doi:10.1002/art.21678
    • Smolen JS, Van Der Heijde DMFM, St Clair EW, Emery P, Bathon JM, et al. (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis and rheumatism 54: 702-710 doi:10.1002/art.21678.
    • (2006) Arthritis and Rheumatism , vol.54 , pp. 702-710
    • Smolen, J.S.1    van der Heijde, D.M.F.M.2    Clair St., E.W.3    Emery, P.4    Bathon, J.M.5
  • 58
    • 8444239359 scopus 로고    scopus 로고
    • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
    • doi:10.1002/art.20568
    • St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and rheumatism 50: 3432-3443 doi:10.1002/art.20568.
    • (2004) Arthritis and Rheumatism , vol.50 , pp. 3432-3443
    • Clair St., E.W.1    van der Heijde, D.M.F.M.2    Smolen, J.S.3    Maini, R.N.4    Bathon, J.M.5
  • 59
    • 84855850269 scopus 로고    scopus 로고
    • Safety of abatacept or infliximab in RA patients with an inadequate response to MTX: Results from a 1-year double-blind randomized clinical trial
    • van Vollenhoven RF, Schiff M, Keiserman M, Codding C, Songcharoen S, et al. (2008) Safety of abatacept or infliximab in RA patients with an inadequate response to MTX: Results from a 1-year double-blind randomized clinical trial. Scandinavian journal of rheumatology Suppl 123: 52.
    • (2008) Scandinavian Journal of Rheumatology Suppl , vol.123 , pp. 52
    • van Vollenhoven, R.F.1    Schiff, M.2    Keiserman, M.3    Codding, C.4    Songcharoen, S.5
  • 60
    • 0142029652 scopus 로고    scopus 로고
    • The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate
    • Bathon JM, Genovese MC, (2003) The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clinical and experimental rheumatology 21: 195-197.
    • (2003) Clinical and Experimental Rheumatology , vol.21 , pp. 195-197
    • Bathon, J.M.1    Genovese, M.C.2
  • 62
    • 48149100741 scopus 로고    scopus 로고
    • Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
    • doi:10.1016/S0140-6736(08)61000-4
    • Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, et al. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372: 375-382 doi:10.1016/S0140-6736(08)61000-4.
    • (2008) Lancet , vol.372 , pp. 375-382
    • Emery, P.1    Breedveld, F.C.2    Hall, S.3    Durez, P.4    Chang, D.J.5
  • 63
    • 77649159374 scopus 로고    scopus 로고
    • Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study
    • doi:10.1002/art.27268
    • Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, et al. (2010) Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis and rheumatism 62: 674-682 doi:10.1002/art.27268.
    • (2010) Arthritis and Rheumatism , vol.62 , pp. 674-682
    • Emery, P.1    Breedveld, F.2    van der Heijde, D.3    Ferraccioli, G.4    Dougados, M.5
  • 64
    • 0036274944 scopus 로고    scopus 로고
    • Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes
    • doi:10.1002/art.10308
    • Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, et al. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis and rheumatism 46: 1443-1450 doi:10.1002/art.10308.
    • (2002) Arthritis and Rheumatism , vol.46 , pp. 1443-1450
    • Genovese, M.C.1    Bathon, J.M.2    Martin, R.W.3    Fleischmann, R.M.4    Tesser, J.R.5
  • 65
    • 53149141023 scopus 로고    scopus 로고
    • Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
    • doi:10.1136/ard.2008.094524
    • Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, et al. (2008) Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Annals of the rheumatic diseases 67: 1444-1447 doi:10.1136/ard.2008.094524.
    • (2008) Annals of the Rheumatic Diseases , vol.67 , pp. 1444-1447
    • Kavanaugh, A.1    Klareskog, L.2    van der Heijde, D.3    Li, J.4    Freundlich, B.5
  • 66
    • 1042290332 scopus 로고    scopus 로고
    • Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial
    • doi:10.1002/art.20019
    • Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, et al. (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism 50: 353-363 doi:10.1002/art.20019.
    • (2004) Arthritis and Rheumatism , vol.50 , pp. 353-363
    • Keystone, E.C.1    Schiff, M.H.2    Kremer, J.M.3    Kafka, S.4    Lovy, M.5
  • 67
    • 10744223002 scopus 로고    scopus 로고
    • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
    • doi:10.1016/S0140-6736(04)15640-7
    • Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-681 doi:10.1016/S0140-6736(04)15640-7.
    • (2004) Lancet , vol.363 , pp. 675-681
    • Klareskog, L.1    van der Heijde, D.2    de Jager, J.P.3    Gough, A.4    Kalden, J.5
  • 68
    • 8344285150 scopus 로고    scopus 로고
    • A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double -blind, randomized, placebo -controlled study
    • Lan J-L, Chou S-J, Chen D-Y, Chen Y-H, Hsieh T-Y, et al. (2004) A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. Journal Of The Formosan Medical Association 103: 618-623.
    • (2004) Journal Of The Formosan Medical Association , vol.103 , pp. 618-623
    • Lan, J.-L.1    Chou, S.-J.2    Chen, D.-Y.3    Chen, Y.-H.4    Hsieh, T.-Y.5
  • 70
    • 37149038223 scopus 로고    scopus 로고
    • Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
    • doi:10.1002/art.23141
    • van der Heijde D, Klareskog L, Landewé R, Bruyn GAW, Cantagrel A, et al. (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis and rheumatism 56: 3928-3939 doi:10.1002/art.23141.
    • (2007) Arthritis and Rheumatism , vol.56 , pp. 3928-3939
    • van der Heijde, D.1    Klareskog, L.2    Landewé, R.3    Bruyn, G.A.W.4    Cantagrel, A.5
  • 71
    • 33646365588 scopus 로고    scopus 로고
    • Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial
    • doi:10.1002/art.21655
    • van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, et al. (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis and rheumatism 54: 1063-1074 doi:10.1002/art.21655.
    • (2006) Arthritis and Rheumatism , vol.54 , pp. 1063-1074
    • van der Heijde, D.1    Klareskog, L.2    Rodriguez-Valverde, V.3    Codreanu, C.4    Bolosiu, H.5
  • 72
    • 0033611472 scopus 로고    scopus 로고
    • A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
    • doi:10.1056/NEJM199901283400401
    • Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. The New England journal of medicine 340: 253-259 doi:10.1056/NEJM199901283400401.
    • (1999) The New England Journal of Medicine , vol.340 , pp. 253-259
    • Weinblatt, M.E.1    Kremer, J.M.2    Bankhurst, A.D.3    Bulpitt, K.J.4    Fleischmann, R.M.5
  • 73
    • 31044442965 scopus 로고    scopus 로고
    • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    • doi:10.1002/art.21519
    • Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, et al. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo. Arthritis and rheumatism 54: 26-37 doi:10.1002/art.21519.
    • (2006) Arthritis and Rheumatism , vol.54 , pp. 26-37
    • Breedveld, F.C.1    Weisman, M.H.2    Kavanaugh, A.F.3    Cohen, S.B.4    Pavelka, K.5
  • 74
    • 65549106396 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis
    • doi:10.1016/S0929-6646(09)60071-1
    • Chen D-Y, Chou S-J, Hsieh T-Y, Chen Y-H, Chen H-H, et al. (2009) Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. Journal of the Formosan Medical Association = Taiwan yi zhi 108: 310-319 doi:10.1016/S0929-6646(09)60071-1.
    • (2009) Journal of the Formosan Medical Association = Taiwan Yi Zhi , vol.108 , pp. 310-319
    • Chen, D.-Y.1    Chou, S.-J.2    Hsieh, T.-Y.3    Chen, Y.-H.4    Chen, H.-H.5
  • 75
    • 61549091538 scopus 로고    scopus 로고
    • Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis
    • doi:10.1007/s10067-008-1064-0
    • Jamal S, Patra K, Keystone EC, (2009) Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clinical rheumatology 28: 413-419 doi:10.1007/s10067-008-1064-0.
    • (2009) Clinical Rheumatology , vol.28 , pp. 413-419
    • Jamal, S.1    Patra, K.2    Keystone, E.C.3
  • 77
    • 2342658406 scopus 로고    scopus 로고
    • Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled
    • doi:10.1002/art.20217
    • Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled. Arthritis and rheumatism 50: 1400-1411 doi:10.1002/art.20217.
    • (2004) Arthritis and Rheumatism , vol.50 , pp. 1400-1411
    • Keystone, E.C.1    Kavanaugh, A.F.2    Sharp, J.T.3    Tannenbaum, H.4    Hua, Y.5
  • 78
    • 33847795275 scopus 로고    scopus 로고
    • study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate
    • Kim H-Y, Lee S-K, Song YW, Yoo D-H, Koh E-M, et al. (2007) study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology 10: 9-16.
    • (2007) APLAR Journal of Rheumatology , vol.10 , pp. 9-16
    • Kim, H.-Y.1    Lee, S.-K.2    Song, Y.W.3    Yoo, D.-H.4    Koh, E.-M.5
  • 79
    • 46549084098 scopus 로고    scopus 로고
    • Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study
    • doi:10.1007/s10165-008-0045-0
    • Miyasaka N, (2008) Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Modern rheumatology/the Japan Rheumatism Association 18: 252-262 doi:10.1007/s10165-008-0045-0.
    • (2008) Modern Rheumatology/the Japan Rheumatism Association , vol.18 , pp. 252-262
    • Miyasaka, N.1
  • 80
    • 10744227300 scopus 로고    scopus 로고
    • Efficacy and safety of the fully human anti-tumour necrosis factor monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
    • doi:10.1136/ard.2003.009563
    • van de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, et al. (2003) Efficacy and safety of the fully human anti-tumour necrosis factor monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of the Rheumatic Diseases 62: 1168-1177 doi:10.1136/ard.2003.009563.
    • (2003) Annals of the Rheumatic Diseases , vol.62 , pp. 1168-1177
    • van de Putte, L.B.A.1    Rau, R.2    Breedveld, F.C.3    Kalden, J.R.4    Malaise, M.G.5
  • 81
    • 11144355274 scopus 로고    scopus 로고
    • Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
    • doi:10.1136/ard.2003.013052
    • van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, et al. (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of the rheumatic diseases 63: 508-516 doi:10.1136/ard.2003.013052.
    • (2004) Annals of the Rheumatic Diseases , vol.63 , pp. 508-516
    • van de Putte, L.B.A.1    Atkins, C.2    Malaise, M.3    Sany, J.4    Russell, A.S.5
  • 82
    • 0037231533 scopus 로고    scopus 로고
    • Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial
    • doi:10.1002/art.10697
    • Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and rheumatism 48: 35-45 doi:10.1002/art.10697.
    • (2003) Arthritis and Rheumatism , vol.48 , pp. 35-45
    • Weinblatt, M.E.1    Keystone, E.C.2    Furst, D.E.3    Moreland, L.W.4    Weisman, M.H.5
  • 83
    • 68049099274 scopus 로고    scopus 로고
    • Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-bli
    • doi:10.1002/art.24638
    • Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, et al. (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-bli. Arthritis and rheumatism 60: 2272-2283 doi:10.1002/art.24638.
    • (2009) Arthritis and Rheumatism , vol.60 , pp. 2272-2283
    • Emery, P.1    Fleischmann, R.M.2    Moreland, L.W.3    Hsia, E.C.4    Strusberg, I.5
  • 84
    • 42449157502 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study
    • doi:10.1002/art.23383
    • Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, et al. (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis and rheumatism 58: 964-975 doi:10.1002/art.23383.
    • (2008) Arthritis and Rheumatism , vol.58 , pp. 964-975
    • Kay, J.1    Matteson, E.L.2    Dasgupta, B.3    Nash, P.4    Durez, P.5
  • 85
    • 67449133560 scopus 로고    scopus 로고
    • Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
    • doi:10.1136/ard.2008.099010
    • Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, et al. (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Annals of the rheumatic diseases 68: 789-796 doi:10.1136/ard.2008.099010.
    • (2009) Annals of the Rheumatic Diseases , vol.68 , pp. 789-796
    • Keystone, E.C.1    Genovese, M.C.2    Klareskog, L.3    Hsia, E.C.4    Hall, S.T.5
  • 86
    • 67449123606 scopus 로고    scopus 로고
    • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
    • doi:10.1136/ard.2008.099291
    • Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, et al. (2009) Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Annals of the rheumatic diseases 68: 805-811 doi:10.1136/ard.2008.099291.
    • (2009) Annals of the Rheumatic Diseases , vol.68 , pp. 805-811
    • Fleischmann, R.1    Vencovsky, J.2    van Vollenhoven, R.F.3    Borenstein, D.4    Box, J.5
  • 87
    • 55849112632 scopus 로고    scopus 로고
    • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • doi:10.1002/art.23964
    • Keystone E, Heijde DVD, Mason D, Landewé R, Vollenhoven RV, et al. (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and rheumatism 58: 3319-3329 doi:10.1002/art.23964.
    • (2008) Arthritis and Rheumatism , vol.58 , pp. 3319-3329
    • Keystone, E.1    Heijde, D.V.D.2    Mason, D.3    Landewé, R.4    Vollenhoven, R.V.5
  • 88
    • 67449124634 scopus 로고    scopus 로고
    • Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
    • doi:10.1136/ard.2008.101659
    • Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, et al. (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the rheumatic diseases 68: 797-804 doi:10.1136/ard.2008.101659.
    • (2009) Annals of the Rheumatic Diseases , vol.68 , pp. 797-804
    • Smolen, J.1    Landewé, R.B.2    Mease, P.3    Brzezicki, J.4    Mason, D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.